AbbVie (ABBV) Reports Promising Phase 2a Data for ABBV-466 in Crohn's Disease

gurufocus.com · 2026-10-19

On October 19, 2026, AbbVie Inc (NYSE: ABBV) announced encouraging results from its Phase 2a TARGET-CD study evaluating ABBV-466, a novel dual-target therapy fo

TickrTrends take: AbbVie reported positive interim results for its investigational Crohn's disease treatment, which could strengthen its pipeline and potentially support future revenue growth. However, TickrTrends currently assesses ABBV as overvalued, suggesting that positive clinical developments may already be reflected in the stock price or that current valuations leave limited room for near-term upside. Investors relying on valuation metrics should monitor whether successful phase progression of ABBV-466 eventually justifies the company's current market assessment or whether valuation multiples remain disconnected from clinical progress.

Read the full story at gurufocus.com →